News

Oncology Nurse Advisor24d
Niraparib-Bevacizumab Maintenance Deemed Promising for Recurrent Ovarian Cancer
Phase 2 study of maintenance of niraparib rechallenge plus bevacizumab in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor (KGOG 3056/NIRVANA-R).
ascopubs.org5d
Oregovomab in combination with non-platinum chemotherapy for the treatment of PARP inhibitor– and platinum-resistant ovarian cancer: A two-cohort, single-arm phase 2 study ...
Survival outcomes for ovarian cancer patients in the post–poly ADP-ribose polymerase inhibitor (PARPi) era in the US. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...
ascopubs.org5d
Association of HIPEC response in ovarian cancer with PI3K/RAS/Notch gene signatures: A whole transcriptomic analysis of U.S. and French HIPEC treated ovarian cancer patients.
Real-world analysis of folate receptor alpha (FRα; FOLR1) expression in pan-tumor samples from over 6000 patients in the US. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...